Mangoceuticals Inc (MGRX) Stock Analysis
Verdict: AVOID
Negative 4,600% operating margins and a 3-month cash runway make this a high-probability bankruptcy or dilution candidate.
Investment score: 12/100
Analysis as of
Is Mangoceuticals Inc stock worth reviewing? The TradeMates thesis
MGRX is a distressed micro-cap with terminal financial metrics and no clear catalyst for a turnaround.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Mangoceuticals Inc opportunities and risks
What speaks for MGRX
- Digital Telemedicine Scale
What speaks against MGRX
- Insolvency within 4 months
Peers and competitors
- SRXH
- HEWA
- BLMH
- NGMC
- HESG
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MGRX | n/a | 7.2x | n/a | 52.4% | -4632.9% | -164.2% |
| SRXH | n/a | n/a | n/a | 26.9% | 168.6% | -141.0% |
| HEWA | n/a | 0.2x | 25.1x | 39.5% | -0.7% | -72.6% |
| BLMH | n/a | 0.2x | n/a | 43.9% | -62.2% | -79.7% |
| NGMC | n/a | 0.0x | 7.7x | 31.9% | -2.4% | 0.0% |
| HESG | n/a | 5.2x | n/a | 7.0% | -15.2% | 2.2% |
| Peer median | n/a | 0.2x | n/a | 31.9% | -2.4% | -72.6% |
Frequently asked questions about Mangoceuticals Inc (MGRX)
Is MGRX stock a good investment?
The TradeMates model rates Mangoceuticals Inc as AVOID with an investment score of 12/100. MGRX is a distressed micro-cap with terminal financial metrics and no clear catalyst for a turnaround. This is algorithmic model output, not personal investment advice.
Is MGRX stock a buy?
The TradeMates model verdict for MGRX is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.